Currently, intravitreal Anti-VEGF injections represent the standard treatment modality for a range of conditions, including diabetic retinopathy (DR), diabetic macular edema (DME), age-related macular degeneration (AMD), retinal vein occlusion (RVO), and myopic choroidal neovascularization (mCNV) (1, 2). Here, VEGFA is linked to diabetic macular edema.